Immune Diagnostics Expansion Sight combines AI with a proprietary fluorescent microscopy platform to deliver live immune cell insights, enabling expansion across infectious diseases, oncology, immunotherapy monitoring, and autoimmune conditions. This presents cross-sell opportunities to healthcare providers, CROs, and diagnostic labs seeking a broad immune profiling solution.

Regulatory Ready Platform With FDA clearance for a CBC system and CE marking, Sight demonstrates regulatory readiness and scalable manufacturing. Target prospective customers valuing compliant, clinic-ready immune diagnostics infrastructure to accelerate adoption in hospital networks and point-of-care settings.

Industrial Scale Partnerships The company has secured substantial funding and operates across multiple regions (Israel, US, Europe, Latin America). This indicates a mature path for channel partnerships, integrators, and distribution agreements to penetrate global markets efficiently.

Data-Driven AI Advantage AI-driven digital biomarkers decode immune responses from live blood, offering a unique value proposition beyond incremental biomarker tests. Sell opportunities include biopharma for treatment monitoring, clinical trial endpoints, and personalized medicine programs seeking dynamic immune readouts.

Cross-Product Engine The platform is designed as a versatile engine for multiple products and markets using the same hardware and test kits. This enables upsell/cascading sales within existing customers as new immune signatures, diagnostics panels, or companion tests are developed.